281 related articles for article (PubMed ID: 33245725)
1. HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.
Hart V; Gautrey H; Kirby J; Tyson-Capper A
Oncotarget; 2020 Nov; 11(46):4338-4357. PubMed ID: 33245725
[TBL] [Abstract][Full Text] [Related]
2. The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
Castagnoli L; Ladomery M; Tagliabue E; Pupa SM
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261614
[TBL] [Abstract][Full Text] [Related]
3. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
[TBL] [Abstract][Full Text] [Related]
4. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
5. HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.
Palladini A; Nicoletti G; Lamolinara A; Dall'Ora M; Balboni T; Ianzano ML; Laranga R; Landuzzi L; Giusti V; Ceccarelli C; Santini D; Taffurelli M; Di Oto E; Asioli S; Amici A; Pupa SM; De Giovanni C; Tagliabue E; Iezzi M; Nanni P; Lollini PL
Oncotarget; 2017 Aug; 8(33):54444-54458. PubMed ID: 28903354
[TBL] [Abstract][Full Text] [Related]
6. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.
Pupa SM; Ligorio F; Cancila V; Franceschini A; Tripodo C; Vernieri C; Castagnoli L
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638263
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review.
Sapna F; Athwal PSS; Kumar M; Randhawa S; Kahlon S
Cureus; 2020 Aug; 12(8):e9522. PubMed ID: 32905036
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab in small tumours and in elderly women.
Albanell J; Ciruelos EM; Lluch A; Muñoz M; Rodríguez CA
Cancer Treat Rev; 2014 Feb; 40(1):41-7. PubMed ID: 23659993
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
Schramm A; De Gregorio N; Widschwendter P; Fink V; Huober J
Breast Care (Basel); 2015 Jul; 10(3):173-8. PubMed ID: 26557822
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance.
Jackson C; Browell D; Gautrey H; Tyson-Capper A
Int J Cell Biol; 2013; 2013():973584. PubMed ID: 23935627
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer.
Inoue K; Fry EA
Genet Epigenet; 2015; 7():19-32. PubMed ID: 26692764
[TBL] [Abstract][Full Text] [Related]
14. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
Molina-Crespo Á; Cadete A; Sarrio D; Gámez-Chiachio M; Martinez L; Chao K; Olivera A; Gonella A; Díaz E; Palacios J; Dhal PK; Besev M; Rodríguez-Serrano M; García Bermejo ML; Triviño JC; Cano A; García-Fuentes M; Herzberg O; Torres D; Alonso MJ; Moreno-Bueno G
Clin Cancer Res; 2019 Aug; 25(15):4846-4858. PubMed ID: 31064780
[TBL] [Abstract][Full Text] [Related]
15. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.
Chong QY; You ML; Pandey V; Banerjee A; Chen YJ; Poh HM; Zhang M; Ma L; Zhu T; Basappa S; Liu L; Lobie PE
Oncotarget; 2017 Sep; 8(43):74188-74208. PubMed ID: 29088778
[TBL] [Abstract][Full Text] [Related]
16. The expanding role of pertuzumab in the treatment of HER2-positive breast cancer.
Moya-Horno I; Cortés J
Breast Cancer (Dove Med Press); 2015; 7():125-32. PubMed ID: 26056489
[TBL] [Abstract][Full Text] [Related]
17. The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.
González-Alonso P; Zazo S; Martín-Aparicio E; Luque M; Chamizo C; Sanz-Álvarez M; Minguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Piersma SR; Jimenez CR; Madoz-Gúrpide J; Rojo F
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365528
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer.
Labidi S; Mejri N; Lagha A; Daoud N; El Benna H; Afrit M; Boussen H
Breast Care (Basel); 2016 Dec; 11(6):418-422. PubMed ID: 28228709
[TBL] [Abstract][Full Text] [Related]
19. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.
Wilson FR; Coombes ME; Wylie Q; Yurchenko M; Brezden-Masley C; Hutton B; Skidmore B; Cameron C
Syst Rev; 2017 Oct; 6(1):196. PubMed ID: 29017563
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
